GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules to treat cancer, osteoporosis and bone loss, muscle wasting, and other serious medical conditions in the United States. The company markets FARESTON tablets for the treatment of metastatic breast cancer in postmenopausal women through wholesale drug distributors. Its product candidates in clinical development include ACAPODENE, a selective estrogen receptor modulator, which is in pivotal Phase III clinical trials for the treatment of multiple serious side effects of androgen deprivation therapy, for advanced prostate cancer; and for the prevention of prostate cancer in high risk men with precancerous prostate lesions called high grade prostatic intraepithelial neoplasia (PIN). The company also develops Ostarine, a selective androgen receptor modulator, which is in phase IIb clinical trials for the treatment of cancer cachexia; and for chronic kidney disease, and end-stage renal disease. In addition, GTx develops Andarine for the treatment of various medical conditions relating to muscle wasting and/or bone loss; prostarine for the treatment of benign prostatic hyperplasia; and andromustine, an anticancer product candidate for hormone refractory prostate cancer. It has collaborations with Hybritech, Inc.; diaDexus, Inc.; MacroArray Technologies, LLC; Onconome, Inc.; and Gen-Probe, Incorporated to develop an accurate blood or urine test to detect high grade PIN. GTx also has a research and development, and strategic collaboration with Merck & Co., Inc. for the development of selective androgen receptor modulators. The company was founded in 1997 and is headquartered in Memphis, Tennessee.